Methenamine Hippurate Dosing for rUTI Prophylaxis
The recommended dose of methenamine hippurate for prophylaxis of recurrent uncomplicated cystitis is 1 gram twice daily (morning and night). 1, 2
Standard Dosing Regimen
- Adults and children >12 years: 1 gram (1 tablet) twice daily 2
- Children 6-12 years: 0.5-1 gram twice daily 2
- Duration: Typically continued for 6-12 months based on clinical response 1, 3
This dosing was validated in the landmark ALTAR trial 3, which demonstrated non-inferiority to daily antibiotic prophylaxis using methenamine hippurate 1 gram twice daily over 12 months. The trial showed a substantial reduction in UTI incidence to 1.38 episodes per person-year with this regimen, compared to baseline rates of 5-6 episodes annually in women with rUTI.
Key Clinical Considerations
Urine Acidification
The FDA label 2 states that antibacterial activity is greater in acid urine, and recommends:
- Restriction of alkalinizing foods and medications
- However, the 2025 AUA/CUA/SUFU guidelines 1 explicitly note that urinary acidifiers (such as vitamin C) have NOT been found to significantly lower urinary pH in RCTs and do not enhance methenamine's effects
- Concomitant use of vitamin C with methenamine is unnecessary 1
Treatment Duration & Discontinuation Risk
Recent evidence reveals an important caveat: The ImpresU trial 4 in older women (≥70 years) showed that while methenamine hippurate reduced UTI frequency by 25% during the 6-month treatment period (incidence rate ratio 0.75), discontinuation after 6 months led to a rebound effect with a 70% higher incidence of UTIs in the follow-up period (incidence rate ratio 1.7, p<0.001). This suggests:
- Longer treatment durations may be preferable
- Gradual tapering rather than abrupt discontinuation should be considered
- Patients should be counseled about potential rebound risk upon stopping
Monitoring
- Monitor efficacy through repeated urine cultures 2
- Assess clinical response at 3,6, and 12 months 5
- Formaldehyde is detectable in 85% of patient urines during treatment 6, confirming adequate drug conversion
Guideline Support
Both the 2024 EAU guidelines 7 (strong recommendation) and the 2025 AUA/CUA/SUFU guidelines 1 (conditional recommendation) support methenamine hippurate for rUTI prophylaxis in women without urinary tract abnormalities. The EAU provides stronger endorsement, while the AUA notes this as an effective alternative when non-antimicrobial interventions are preferred.
Advantages of This Regimen
- Non-inferior to antibiotics for UTI prevention 1, 3
- Lower antimicrobial resistance: 56% resistance in methenamine users vs 72% in antibiotic users 3
- Fewer adverse events compared to nitrofurantoin 5
- Lower total management costs despite higher drug costs 5
- Improved quality of life scores (IPSS and SF-36) 5
Important Caveat
While formaldehyde resistance can develop (5.8% of E. coli isolates in ALTAR showed growth in >1 mM formaldehyde) 6, this remains far less problematic than antibiotic resistance patterns. The twice-daily dosing maintains continuous antibacterial activity in urine 2, which is critical for prophylactic efficacy.